neuway pharma gmbh logo

NEUWAY Pharma GmbH

NEUWAY Pharma (Life Science Incubator GmbH spin-off), is a biotech company, focus on the preclinical and clinical development of innovative therapeutics for the treatment of orphan brain diseases based on its proprietary CNS drug delivery platform.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.neuway-pharma.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Ludwig-Erhard-Allee 253175
Bonn
Germany
Email
Contact Number
+49 228 522798-0

In May 2016, AbbVie, Germany and NEUWAY Pharma partners for three years to analyze, validate and use a new technology based on Engineered Protein Capsules (EPC), to transport highly active substances across the blood-brain barrier.

In Feb 2015, University Zurich and NEUWAY entered into a license agreement to develop Engineered Protein Capsules (EPC) technology to treat progressive multifocal leucoencephalopathy (PML), a rare neurological disease.[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”” connections=”true” suffix=””]

NEUWAY technology platform Engineered Protein Capsules (EPC), allows to pack drug molecules in a virus-like particles to transport them across the blood-brain barrier into the CNS and broadens the range of possible drug delivery options.

In Oct 2016, NEUWAY Receives ‹2.95 Million Germany`s Federal Ministry of Education and Research (BMBF) Grant for Advancing CNS Drug Delivery Platform .

In Oct 2015, NEUWAY Pharma complete series A financing and raised ‹ 5.85 Mn in two rounds. The lead investors includes Wellington Partners, Life Science Inkubator and Kreditanstalt fÈr Wiederaufbau (KfW).